Grifols gains FDA approval for new purification plant in Los Angeles
<p>The plant has required investment of €53 millions and will begin operating this year</p>
Grifols, a multinational corporation specializing in the pharmaceutical and hospital sectors, has gained approval from the US Food and Drug Administration (FDA) to build a new purification plant in Los Angeles.
The company’s new center, with an investment of €53 millions, will be devoted exclusively to purifying intravenous immunoglobulin (IVIG), a protein from plasma used to treat immunodeficiencies and fight neurological diseases thanks to its high concentration of antibodies –better known as defenses- that act as an immunological barrier for the body.
Intravenous immunoglobulin is one of the most important and widely used plasma proteins marketed by Grifols under the Flebogamma® and Gamunex® brands.
The plant will be located on the company’s industrial complex in Los Angeles. It will have a total surface area of 9,000 square meters and purification capacity of up to 17 million grams of IVIG per year, thus boosting output of Gamunex. The new space is expected to go into operation this year and create more than 100 new jobs.